Shares of Juno Therapeutics Inc (NASDAQ:JUNO) traded down 1.3% on Monday . The company traded as low as $28.42 and last traded at $28.84, with a volume of 1,199,339 shares traded. The stock had previously closed at $29.21.

A number of analysts have weighed in on the company. Vetr cut Juno Therapeutics from a “strong-buy” rating to a “buy” rating and set a $53.00 price objective for the company. in a research report on Monday, June 6th. FBR & Co reaffirmed a “buy” rating on shares of Juno Therapeutics in a research report on Monday, June 6th. Zacks Investment Research cut Juno Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, April 25th. SunTrust Banks Inc. reaffirmed a “buy” rating and set a $50.00 price objective on shares of Juno Therapeutics in a research report on Wednesday, April 20th. Finally, Raymond James Financial Inc. began coverage on Juno Therapeutics in a research report on Thursday, June 2nd. They set an “outperform” rating and a $52.00 price objective for the company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $54.84.

The company’s market capitalization is $2.88 billion. The firm has a 50-day moving average of $39.61 and a 200-day moving average of $37.82.

Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.26. The firm earned $9.80 million during the quarter, compared to the consensus estimate of $4.83 million. During the same period in the previous year, the business earned ($0.30) earnings per share. On average, analysts forecast that Juno Therapeutics Inc will post ($2.28) EPS for the current fiscal year.

In other news, General Counsel Bernard J. Cassidy sold 3,200 shares of the company’s stock in a transaction that occurred on Tuesday, April 19th. The stock was sold at an average price of $43.12, for a total transaction of $137,984.00. Following the completion of the transaction, the general counsel now directly owns 57,933 shares of the company’s stock, valued at $2,498,070.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Hans Edgar Bishop sold 90,750 shares of the company’s stock in a transaction that occurred on Thursday, June 9th. The shares were sold at an average price of $46.42, for a total value of $4,212,615.00. Following the transaction, the chief executive officer now directly owns 2,704,609 shares of the company’s stock, valued at $125,547,949.78. The disclosure for this sale can be found here.

Several institutional investors recently bought and sold shares of the stock. BNP Paribas Arbitrage SA raised its position in Juno Therapeutics by 27.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 51,206 shares of the biopharmaceutical company’s stock valued at $2,252,000 after buying an additional 10,884 shares during the period. US Bancorp DE increased its position in shares of Juno Therapeutics by 1.8% in the fourth quarter. US Bancorp DE now owns 88,700 shares of the biopharmaceutical company’s stock valued at $3,900,000 after buying an additional 1,600 shares in the last quarter. BBR Partners LLC acquired a new position in shares of Juno Therapeutics during the fourth quarter valued at about $1,539,000. Baillie Gifford & Co. acquired a new position in shares of Juno Therapeutics during the fourth quarter valued at about $12,312,000. Finally, Stevens Capital Management LP acquired a new position in shares of Juno Therapeutics during the fourth quarter valued at about $2,315,000.

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.